Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)

NCT02043665 is registered in ClinicalTrials.gov with Viralytics as lead sponsor.

NCT NCT02043665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02043665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Lead sponsor
Viralytics
Phase
Phase 1
Overall status
Completed
Start date
December 18, 2013
Completion date
January 10, 2020
Enrollment
85 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, non-small cell lung cancer